What’s new in neuromyelitis optica spectrum disorder treatment?

Yi-Ching Chu¹, Tzu-Lun Huang²*

Abstract
Optic neuritis, an optic nerve inflammatory disease presenting with acute unilateral or bilateral visual loss, is one of the core symptoms of neuromyelitis optica spectrum disorder (NMOSD). The diagnosis of NMOSD-related optic neuritis is challenging, and it is mainly based on clinical presentation, optical coherence tomography, magnetic resonance imaging scans, and the status of serum aquaporin-4 antibodies. In the pathogenesis, aquaporin-4 antibodies target astrocytes in the optic nerves, spinal cord and some specific regions of the brain eliciting a devastating autoimmune response. Current pharmacological interventions are directed against various steps within the immunological response, notably the terminal complement system, B-cells, and the pro-inflammatory cytokine Interleukin 6 (IL6). Conventional maintenance therapies were off-label uses of the unspecific immunosuppressants azathioprine and mycophenolate mofetil as well as the CD20 specific antibody rituximab and the IL6 receptor specific antibody tocilizumab. Recently, four phase III clinical trials demonstrated the safety and efficacy of the three novel biologics eculizumab, inebilizumab, and satralizumab. These monoclonal antibodies are directed against the complement system, CD19 B-cells and the IL6 receptor, respectively. All three have been approved for NMOSD in the US and several other countries worldwide and thus provide convincing treatment options.

Keywords:
Aquaporin-4-, eculizumab, inebilizumab, neuromyelitis optica spectrum disorder, optic neuritis, satralizumab

Introduction
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) which predominantly affects the optic nerves and spinal cord. The diagnosis is challenging because NMOSD-associated optic neuritis (NMOSD-ON) is mimicking other optic neuropathies¹¹ and some patients may present subtle contrast sensitivity or color vision loss with nearly normal visual acuity and disc appearance initially. Current treatments for NMOSD include corticosteroids, plasmapheresis, and immunosuppressants. Recently, new biologics showed a better outcome in disease control with reduced relapse risk. In this paper, we provided a comprehensive review of NMOSD and new biologic therapies from an ophthalmologist’s perspective.

Disease Classification
Cases clinically diagnosed as NMOSD may include aquaporin 4 (AQP4)-antibody-seropositive (AQP4-IgG⁺) NMOSD, myelin oligodendrocyte glycoprotein-(MOG)-antibody-seropositive (MOG-IgG⁺) NMOSD, and double-seronegative NMOSD.

Epidemiology and Demographics
NMOSD is a rather rare disease with a worldwide prevalence between 0.5 and 10 per 100,000 persons.²³ Several studies suggest geographic or ethnic differences in prevalence, with Asian and African descents having higher risk of NMOSD.³⁴ The prevalence per 100,000 is around 1 in White populations.
Asian populations (Japanese, Chinese, and Koreans) and 10 in African populations. The latest available epidemiological data for NMOSD in Taiwan from 2015 report an prevalence of only 1.47 and a respective age-standardized annual incidence rate of 0.61. [5]

Geographic or ethnic differences are also evident regarding the age at disease onset. Blacks and Asians tend to be younger at disease onset than Whites (Blacks: 28–33 years, Asians: 35–40 years, Whites: 44 years). [2] Cohort studies from the UK and Japan revealed that ON was the onset phenotype in 41% of the total NMOSD cases (UK: 37%, Japan: 65%) and 86% of the patients showed relapsing disease courses. [6] The age at disease onset appeared to be an important predictor of disability type. AQP4-IgG+ NMOSD patients with young-onset in the UK, but not in Japan, were more likely to have ON as onset attack with higher severity, while older-onset patients in both countries often developed myelitis with poor recovery as the initial presentations. There was prominent female predominance of 87% (UK: 81%, Japan: 98%) in AQP4-IgG+ subpopulation. [2,5] The majority of NMOSD patients are considered AQP4-IgG+. [9] From the remaining cases, a significant proportion of 7% to 42% are seropositive for MOG-IgG. [3] In the Catalonia NMOSD prevalence study, 12% of NMOSD cases were MOG-IgG+. [10] The prevalence of MOG-IgG+ NMOSD was calculated to be 0.11 per 100,000. A recent meta-analysis revealed that 9.3% of all NMOSD patients present with MOG-IgG+. [11] Unlike AQP4-IgG+ NMOSD, which is more common in Asian regions, Asian patients did not differ significantly from European patients in MOG-IgG+ frequency (31.0% vs. 34.3%). In addition, the female to male ratio is 1:1 in MOG-IgG+ NMOSD. MOG-IgG+ NMOSD is more common in children and coexisting autoimmune is rare.

The relapses of NMOSD cause accumulating damage that leads to disability requiring a wheelchair or blindness in 50% or 62% of the cases, respectively, five years after onset, [12] and consequently lead to an impaired quality of life. [13]

**Diagnosis**

The evolution of NMOSD diagnosis shows the challenge in the diagnosis with variable clinical symptoms. In 1999, Wingerchuk *et al.* proposed the first diagnostic criteria for NMO based on clinical and radiographic features. [14] After discovering AQP4-IgG, in 2007 these criteria were revised to consist of the presence of ON and transverse myelitis (TM), two out of three of a longitudinally extensive transverse myelitis (i.e., more than three vertebral segments), brain magnetic resonance imaging (MRI) lesions excluding multiple sclerosis (MS), and AQP4-IgG+ status. [15] These criteria were 99% sensitive and 90% specific for the diagnosis of NMO and have been independently validated. However, after then there were still some suspicious patients who were not able to fulfill the two out of three criteria and failed to confirm NMO diagnosis. In 2015, the diagnosis criteria from International Panel for Neuromyelitis Optica Diagnosis were revised to adapt the earlier diagnosis of acute ON named as NMOSD with or without positive AQP4-IgG. [16] Thereafter, ophthalmologists take the essential role in the clinical diagnosis of NMOSD.

These new NMOSD diagnosis criteria are based on six core clinical characteristics, the presence of serum AQP4-IgG, and ancillary evaluation for AQP4-IgG seronegative (AQP4-IgG-) patients. [16] These core clinical characteristics are ON, acute TM, area postrema syndrome, acute brainstem syndrome, symptomatic narcolepsy, and symptomatic cerebral syndrome. For AQP4-IgG+ patients, only one core clinical characteristic is required for the diagnosis. Before confirming the status of AQP4-IgG, an ophthalmologist can narrow down to the diagnosis of NMOSD-ON by ruling out other retinal diseases, optic neuropathy or brain pathology by pupil response, contrast sensitivity testing (CST), visual field test (VF), optical coherence tomography (OCT) findings, and fluoresce angiography (FA).

Seronegative NMOSD requires some more characteristics to be diagnosed as detailed in Figure 1. For the assessment of AQP4-IgG, it is highly recommended to apply cell-based assays (CBA) that have been shown to be sensitive and highly specific with significantly better performance compared to tissue-based and ELISA assays. [17] Recently, MOG-IgG+ of seronegative NMOSD is categorized into MOG antibody-associated disease, representing a group of inflammatory demyelinating disorders. Therefore, the diagnosis of MOG-IgG+ NMOSD should be very cautious. CBA for MOG-IgG is recommended. [18] The clinical differentiation between AQP4-IgG+ and MOG-IgG+ related ON can be assessed by contrast MRI evaluating disc morphology, laterality, thickness loss of the ganglion cell-inner plexiform layer (GC-IPL), and ON length and site involvement.

The differential diagnosis of NMOSD-ON includes inflammatory, infectious, compressive, ischemic, infiltrative and hereditary optic neuropathy [Figure 2]. The diagnosis is based on various aspects including clinical history, physical examination, ancillary test, serum tests, and MRI. The physical examination including the relative afferent pupillary defect and the morphology of optic nerve head as well as reviewing medical history and the pattern of disease progression may guide to correct diagnosis of acute optic neuropathy. Ancillary testing in ophthalmology...
such as VF, OCT, CST, and/or FA are performed for clinical differential diagnosis. Serum tests such as Treponema pallidum particle agglutination assay, rapid plasma reagin, and quantiferon TB gold test are crucial to rule out the infectious ON caused by syphilis or tuberculosis. Tests for antinuclear antibodies or rheumatoid factor are performed to exclude autoimmune optic neuropathies [Figure 3]. The NMOSD-ON is finally confirmed by the positivity of the serum AQP4-IgG or MOG-IgG and the inflammatory lesion of the optic nerve in orbital MRI. The NMOSD-ON patient will receive high-dose corticosteroid pulse therapy with methylprednisolone (IVMP) for 5 days with and without add-on plasmapheresis (plasma exchange [PLEX]) as soon as possible to reverse the visual function and lessen the acute inflammatory optic nerve damage via blood-optic nerve barrier disruption and decrease retinal ganglion cell die with axon loss in the end [Figure 4].

Clinical Presentation of Optic Neuritis in Neuromyelitis Optica Spectrum Disorder

The acute attack of ON and TM can occur sequentially or even simultaneously.[19] In contrast to MS, disability in NMOSD arises from relapse episodes and progressive forms are rarely noted in NMOSD.[20] In MS, the disease progression to disability including blindness is slow and takes 10 to 15 years.

Generally, ON presents as acute, unilateral, or bilateral vision loss [Table 1]. In NMOSD, the final best-corrected visual acuity of patients with MOG-ON is often better than that of AQP4-ON. In a 3-year-follow-up cohort in China, only 25% of the patients with AQP4-ON had a VA ≥20/25, and more than 45% had a VA <20/200, whereas 85% of the patients with MOG-ON had a VA ≥20/25.[21] Optic disc may be swelling at presentation. The prevalence of disc swelling is higher in MOG-ON than AQP4-ON.[22] There seems to be variable findings of VF defects in both AQP4-ON and MOG-ON compared to central scotoma in MS, and even hemianopia could be noted in AQP4-ON.[27]

In the first acute attack, the NMOSD-related ON leads to variable peripapillary retinal nerve fibre layer (pRNFL) thickness and a remarkable thinning of the GC-IPL in OCT studies.[28] In the subacute phase, the thinning of both pRNFL and GC-IPL is noticed. MOG-ON and AQP4-ON do not differ significantly in RNFL and GC-IPL thickness. Recently, the emerging OCT angiography gave more information about microvascularization. Reduced peripapillary and parafoveal vessel density was observed, and it seemed to be correlated with the visual potential of NMOSD-ON.[29] The relevant functional and structural aspects of AQP4-IgG+ and MOG-IgG+ patients are presented in Figure 5 and Table 1.

MRI image characteristics add substantially to the differential diagnosis of NMOSD-ON [Figure 6a and b]. AQP4-ON preferentially presents with longer, unilateral, or bilateral, more posterior portion of optic nerve with T1 gadolinium enhancement [Figure 6c, e and g].[30] However, MOG-ON usually presents with longer, bilateral, and more anterior portion of optic nerve accompanied by intraorbital optic nerve swelling, and perineural T1 gadolinium enhancement [outlined by arrow head along the optic nerve, Figure 6d, f and h].
Pathological Mechanism

The pathological mechanism of NMOSD may be caused by peripheral autoimmune dysregulation which in turn leads to CNS damage [Figure 7]. AQP4-IgG has been found to have an important role in the pathological mechanism for NMOSD. An impaired innate immune system is thought to promote autoreactive AQP4-IgG specific CD20 B-cells[31-33] that are then differentiated to CD19 positive autoantibody producing plasmablasts. A leaky blood brain barrier (BBB) contributes to the migration of AQP4-IgG from the periphery into the CNS. AQP4-IgG bind to AQP4, expressed on the perivascular astrocyte foot, and activates the complement cascade (complement-dependent cytotoxicity; complement-dependent cell-mediated cytotoxicity) eliciting antibody-dependent cellular cytotoxicity (ADCC) by its Fc domain.[34] Cytokine and chemokine production recruits eosinophils and neutrophils to the inflammation site. After degranulation of neutrophils, astrocytes and nearby oligodendrocyte are damaged. This leads to secondary axonal degeneration and neuronal death.[30]
Interleukin 6 (IL6) signalling is the key player in NMOSD pathophysiology. This is reflected by a strong association of IL6 CSF and serum levels with important disease markers, e.g., EDSS score and CSF cell counts. Notably, the elevated IL6 levels are observed in both AQP4 IgG and MOG IgG NMOSD, but not MS patients. In the pathological mechanisms, IL6 signaling is thought to contribute in multiple ways. IL6 induces naïve T-cell differentiation to Th17 that are supportive for AQP4 specific activated B-cells. IL6 activates B-cell differentiation to plasmablasts and the production of AQP4-IgG. IL6 contributes to an increased BBB permeability and thus antibody and cell infiltration into the CNS. In response to stimulation by proinflammatory cytokines produced by infiltrated granulocytes and microglia, astrocytes produce IL6 as well. Thus, this contributes to the vicious circle of inflammation. Inflammation causes secondary demyelination, contributes to oligodendrocyte and axon damage and leads to neuron loss. In a novel in vitro BBB model, the proposed role of IL6 on the BBB was later confirmed. AQP4-IgG induced the IL6 release from astrocytes, the BBB was impaired by the IL6 signalling to the endothelial cells, and the BBB impairment was reversed by an anti IL6 receptor (IL6R) antibody.

There are several pharmacological targets within these pathways for the maintenance therapies of NMOSD. Azathioprine and mycophenolate mofetil lead to an unspecific suppression of fast-dividing immune cells and thus depleting of T-cell and B-cell. Monoclonal antibodies, rituximab (specifically binds to CD20) and inebilizumab (specifically binds to CD19), induce B-cell depletion as well. Eculizumab specifically binds to complement C5 and blocks all terminal pathways of complement activation. Tocilizumab and satralizumab specifically bind to IL6 receptors and therapy interfering with pathological pathways at multiple sites.

**Management of Acute Attacks**

The timely management of acute attacks is crucial as the physical impairment in NMOSD accumulates with each relapse. Irreversible damages may be prevented by a reduction of the acute inflammation. The mainstay of acute treatment is high-dose IVMP with 1000 mg for 3–5 days. An early initiation of treatment within a few days seems to be associated with a better clinical outcome. Another study emphasized the importance of an early intervention to reduce retinal nerve fiber layer loss. In any way, a complete response to high-dose corticosteroids is observed in only 36% of NMOSD cases. For severe and steroid refractory cases, an escalation therapy with PLEX alone or in combination with high-dose corticosteroids is observed in a few cases. Azathioprine and mycophenolate mofetil lead to an unspecific suppression of fast-dividing immune cells and thus depleting of T-cell and B-cell.
combination with steroids can be considered. PLEX in combination with corticosteroids increases the chances for the returning of EDSS to baseline as well as improves VA compared steroid monotherapy. PLEX, even as monotherapy, showed superiority over steroid monotherapy for VA and VF. However, an early intervention of PLEX <20 days after onset, with or without concomitant use of high-dose IVMP, is strongly encouraged to improve clinical outcome. After confirmation of diagnosis and complete pulse therapy, tapering oral methylprednisolone (1 mg/kg) for several months can be considered until preventive immunosuppressive treatment is initiated and effective. A small study in ten patients suggested that intravenous immunoglobulin (IVlg) followed by oral steroids was effective in four patients with bilateral NMOSD-ON who did not respond to previous IVMP and PLEX therapy. A recent retrospective study showed that IVlg monotherapy for acute NMOSD is in debate, however, the sequential treatment for IVlg and high-dose intravenous corticosteroids can be justified for patients with high EDSS at onset.

### Maintenance Therapy – Prevention of Relapses

The prevention of recurrent attacks is crucial for NMOSD treatment as the disability in patients mainly arise from the accumulation of relapses. Conventional maintenance therapies are based mainly on the off-label use of rituximab, azathioprine, and mycophenolate mofetil. More recently, tocilizumab was proposed as an alternative treatment option. All of them reduce the relapse risk and will be discussed below in more detail.

---

**Table 1: Clinical characteristics of inflammatory optic neuritis**

| Examine Item | Characteristics | MS-ON | AQP4-ON (80%) | MOG-ON (4%-11%) |
|--------------|----------------|------|--------------|---------------|
| Visual acuity | Mild to moderate | Severe | Moderate to severe |
| BCVA nadir <0.1 (20/200) | Good | Poor (~32.4%) |
| BCVA 3 years <0.1 (20/200) | 18.2% |
| BCVA 3 years <0.8 (20/25) | 25.0% |
| Fundoscopy | Retrobulbar neuritis/disc edema (35%) | Retrobulbar neuritis <papillitis/disc edema (variable) | Bilateral papillitis/disc edema (85%) |
| Disc atrophy without venous sheathing | Disc atrophy and vascular changes with “frosting” |
| OCT | Mild RNFL increase acutely, GC-IPL thinning in early weeks | Variable RNFL thickening acutely, with profound GC-IPL loss |
| Average RNFL thickness 72 (68.2-81.75 µm) | 60 (54.3-65.8 µm) |
| OCTA | OCTA finding | Decreased microvascular densities in macular area and smaller FAZ |
| VF | Diffuse and arcuate, most were (90%) central scotoma | Diffuse, variable, central scotoma (76%), Variable noncentral scotoma (23%) |
| MRI | MRI finding | T1 gadolinium enhancement |

OCT=Optical coherence tomography, OCTA=Optical coherence tomography angiography, VF=Visual field, MRI=Magnetic resonance imaging, BCVA=Best-corrected visual acuity, RNFL=Retinal nerve fibre layer, GC-IPL=Ganglion cell-inner plexiform layer, MS=Multiple sclerosis, ON=Optic neuritis, MME=Microcystic macular edema, RPC=Radial peripapillary capillary, FAZ=Foveal avascular zone, AQP4=Aquaporin-4, MOG=Myelin oligodendrocyte glycoprotein
Although with less evidence, low-dose corticosteroids commonly are used as well to reduce relapses in NMOSD, either as monotherapy or as add-on to conventional immunosuppressants. They may as well be very slowly tapered following the acute therapy of relapses. A recent study on long-term disease course and efficacy of maintenance therapies in Taiwan showed that rituximab and immunosuppressants (i.e. azathioprine or
Mycophenolate mofetil significantly reduce the relapse risks.\textsuperscript{[57]}

Methotrexate, mitoxantrone, tacrolimus, and cyclosporine A are less used for NMOSD due to significant side effects.\textsuperscript{[58]} Importantly, fingolimod, natalizumab, or interferon beta commonly used in MS, may be harmful in NMOSD because it may exacerbate disease activity.\textsuperscript{[59–61]}

The US-Food and Drug Administration (US-FDA) approved the three monoclonal antibodies eculizumab, inebilizumab, and satralizumab. The clinical trials that led to the approvals will be discussed in detail below. Relevant off-label and FDA approved therapies that are currently in use are summarized in Figure 8.\textsuperscript{[62]}

Azathioprine interferes with lymphocyte proliferation and thereby decreases total lymphocyte and B cell counts for several weeks to months. A recent meta-analysis with 1016 NMOSD patients reported an annual relapse rate (ARR) reduction of 1.16.\textsuperscript{[63]} However, several further studies suggest that azathioprine might be less effective than rituximab and Mycophenolate mofetil.\textsuperscript{[64–66]} Additionally, a poor tolerability and relapses from breakthrough or delayed onset of action cause discontinuation rates of up to 50% during 18 months of treatment.\textsuperscript{[67]}

Mycophenolate mofetil is another inhibitor of lymphocyte proliferation. Two recent meta-analysis with 1047 and 930 patients reported ARR reductions of 1.13 and 1.17 respectively.\textsuperscript{[68,69]} A comparative study revealed that mycophenolate mofetil is similar to rituximab in terms of ARR and EDSS, but with a failure rate of 36%.\textsuperscript{[70]} According to two studies, efficacy and safety of mycophenolate mofetil was comparable in AQP4-IgG\textsuperscript{+} and AQP4-IgG\textsuperscript{−} patients.\textsuperscript{[64,71]}

Rituximab, initially approved for the treatment of non-Hodgkin B-cell lymphomas, is a chimeric monoclonal anti-CD20 antibody inducing B-cell depletion. The pathogenic role of B-cells, differentiating to auto-antibody producing plasmablasts, justifies the use of rituximab in NMOSD. Based on several open-label, uncontrolled and nonrandomized observational studies demonstrating safety and efficacy in NMOSD, rituximab became a well-established option for relapse prevention. Main safety concerns are infections, Hepatitis B reactivation, infusion-related reactions, and, at long-term use, hypogammaglobulinemia and prolonged neutropenia. Recently, rituximab was tested in phase III rituximab was tested in the RIN1 trial,\textsuperscript{[72]} a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial in Japan for treating NMOSD. At 72 weeks, 7 of 19 patients (37%) who received placebo experienced relapse, while rituximab (0 of 19 patients) completely prevented relapse. A limitation of this trial is the small sample size, which does not allow for quantification risk reduction by rituximab. Under B cell monitoring, the interval of infusions was extended to 9 months, while NMO relapse was suppressed with an ARR of 0.18.\textsuperscript{[73]}

Figure 7: Pathogenesis and drug targets in NMOSD. NMOSD = Neuromyelitis Optica Spectrum Disorder, AQP4-IgG = Aquaporin 4 immunoglobulin G, MOG-IgG = Myelin oligodendrocyte glycoprotein immunoglobulin G, BBB = Blood–brain barrier, CNS = Central nervous system, IL6 = Interleukin 6, ADCC = Antibody-dependent cellular cytotoxicity, CDC = Complement-dependent cellular cytotoxicity, CDCC = Complement-dependent cellular cytotoxicity.
Tocilizumab is a humanized monoclonal antibody that targets the IL6 receptor and is used for the treatment of rheumatoid arthritis and systemic juvenile idiopathic arthritis. In NMOSD, Tocilizumab is supposed to block the IL6 mediated inflammatory cascade, notably the stimulation of plasmablasts and thereby reducing the production of auto-antibodies AQP4-IgG as well as MOG-IgG that are the keys of NMOSD pathogenesis. Several retrospective studies showed the efficacy and safety of Tocilizumab in NMOSD. Tocilizumab was compared with azathioprine in a head-to-head prospective, randomized open label phase II study (TANGO trial) in NMOSD. Both groups had 59 patients with 85% and 90% AQP4-IgG+, respectively. Whereas only eight patients (14%) relapsed in the tocilizumab group, 28 (47%) patients relapsed in the azathioprine group (76% reduction). In the AQP4-IgG+ subgroup, risk reduction was 79% in the tocilizumab group compared to azathioprine. Although the effect of tocilizumab was not significant for the AQP4-IgG- patients of the TANGO trial, a reduced relapse probability was recently shown in MOG IgG patients.

Eculizumab

Eculizumab is a humanized monoclonal antibody that targets C5 of the complement, preventing its cleavage into C5a and C5b and thus inhibiting downstream effector mechanisms of the complement system. The involvement of the complement system in the pathogenesis of NMOSD is well established and an early open-label study showed very encouraging results with eculizumab in NMOSD patients. Eculizumab was then the first one entering a pivotal phase III trial in NMOSD. PREVENT was a multicenter, international, phase III, double blind, randomized, placebo-controlled, time-to-event clinical trial in NMOSD. Importantly, the trial included only AQP4-IgG+ patients and patients were allowed continuing their prior immunosuppressive therapies (e.g., azathioprine and mycophenolate mofetil) in addition to the trial medication. Based on previous safety observations, patients were vaccinated against Neisseria meningitides before inclusion.

In the eculizumab group, the risk of adjudicated relapses was significantly reduced by 94% compared with placebo. The subgroup analysis for patients without concomitant immunosuppressive therapies revealed that none of the patients receiving eculizumab had any relapses at 96 weeks compared to 40% relapse free participants in the placebo group. As regards secondary endpoints, significant effects for adjudicated ARR but no inferences for disability and QoL were observed in eculizumab compared to placebo. Adverse events were comparable among treatments. There was one death in the eculizumab group due to pulmonary empyema. In June 2019, it became the first US-FDA approved treatment for AQP4-IgG+ NMOSD in addition to approval for paroxysmal nocturnal haemoglobinuria and atypical haemolytic uremic syndrome.

Inebilizumab

Targeting B-cells turned out to be a successful strategy in NMOSD treatment. Rituximab, an anti-CD20 antibody, led to the development of inebilizumab, a humanized monoclonal antibody targeting CD19. Inebilizumab eliminated a broader lineage of CD-19-expressing B cells, ranging from pre-B cells to plasmablasts and some plasma cells.

Inebilizumab was tested in the Phase II/III trial, N-MOmentum, that led to the approval of inebilizumab in the US and several other countries worldwide.
N-MOmentum was a multicentre, international, phase III, double blind, randomized, placebo-controlled, time-to-event clinical trial in NMOSD. The trial enrolled AQP4-IgG⁺ (n = 212) or negative (n = 18) patients. All participants started with a short course of oral prednisolone as co-medication to prevent early relapses after B-cell therapy initiation but thereafter no background immunosuppressive therapy was allowed. Compared with placebo, inebilizumab reduced the risk of a relapse by 73%. In the AQP4-IgG⁺ subgroup, risk reduction was 77% in the inebilizumab group compared to placebo. In addition, inebilizumab was associated with the improvements in disability, MRI lesions and NMOSD-related hospitalizations. Type and frequency of adverse events were similar in inebilizumab and placebo groups. Two patients died during the open-label phase, one due to respiratory insufficiency and the second death was indeterminate.

**Satralizumab**

Satralizumab originates from tocilizumab but is a next-generation antibody specifically designed for NMOSD. The introduction of a novel antibody-recycling technology led to increased duration of antibody circulation. Similarly to tocilizumab, satralizumab is a humanized monoclonal antibody targeting the IL-6 receptor in both membrane-bound and soluble forms. Due to the modifications by the antibody-recycling technology, satralizumab rapidly dissociate from IL-6R within the acidic environment of the endosome while maintaining its binding affinity to IL-6R in plasma. This improved the half-life of antigen (~30 days) and thereby allows extending the interval of re-dosing. In addition, satralizumab’s isofrom is IgG2 which reduces the undesired responses such as ADCC and CDC caused by general IgG1 therapeutic antibodies. Moreover, satralizumab exhibits 4-fold higher binding affinity for IL-6R compared with tocilizumab under neutral pH condition and a low isoelectric point to reduce nonspecific clearance in the bloodstream. The engagement of satralizumab for NMOSD enables maximal suppression of IL-6 signalling and practical dosing, while minimizing safety risks in a chronic disease setting.

Satralizumab was tested in two Phase III trials, SAkuraStar and SAkuraSky, that both were multicenter, international, phase III, double blind, randomized, placebo-controlled, time-to-event, clinical trials in NMOSD. The trials were not restricted to AQP4-IgG⁺ patients.

SAkuraSky (on immunosuppressive background) revealed a 62% relapse risk reduction in satralizumab compared with placebo. In the AQP4-IgG⁺ subgroup, satralizumab significantly reduced the risk of relapse by 79% compared with placebo.

In SAkuraStar (monotherapy), a 55% relapsed risk reduction was observed. In the AQP4-IgG⁺ subgroup, satralizumab significantly reduced the risk of relapse by 74% compared with placebo. However, the secondary endpoints for fatigue, pain and EDSS change did not significantly improve under satralizumab. Adverse events were similar among treatments in both satralizumab trials. No deaths and anaphylactic reactions were reported.

SAkuraStar and SAkuraSky finally led to the approval of satralizumab in Taiwan and several other countries worldwide. In Taiwan, where satralizumab is currently the only approved drug for NMOSD, it is marketed as Enspryng® for the treatment of NMOSD in adult and adolescent over 12 years old AQP4-IgG⁺ patients.

**Summary of Eculizumab, Inebilizumab, and Satralizumab**

The four pivotal Phase III clinical trials for eculizumab, inebilizumab, and satralizumab are summarized in Table 2. Many major differences in the design of these trials are discussed below.

First, the age for enrolment in both PREVENT (eculizumab) and N-MOmentum (inebilizumab) trials was ≥18 years; SAkuraSky (satralizumab) enrolled adolescent (<18 years), adult and elderly patients (>65 years), and SAkuraStar (satralizumab) enrolled patients aged 18–74 years. Second, the status of antibodies in enrolled patients was different. PREVENT trial restricted the population to AQP4-IgG⁺ patients. Less than 10% of patients in the N-MOmentum trial were AQP4-IgG seronegative. SAkura studies contain approximately one third of AQP4-IgG seronegative patients. Third, continuing other medication is different between trials. PREVENT and SAkuraSky allowed continuing prior immunosuppressive therapies, N-MOmentum and SAkuraStar were conducted as monotherapies. Finally, inclusion criteria are not equal to each other trial. PREVENT recruited patients with at least 2 relapses in the past 12 months or a history of 3 relapses in the past 24 months. N-MOmentum enrolled patients with at least 1 attack in the past 12 months or at least two relapses in the 24 months. SAkuraStar enrolled patients who had experienced at least one attack or relapse in the past 12 months. SAkuraSky enrolled patients with at least 2 relapses within 24 months and one of those relapses within the previous 12 months.

All four trials used an adjudication committee for relapse assessment, but different relapse criteria were
adopted. For PREVENT, the adjudication systems with criteria with EDSS/Optico–Spinal Impairment Scale score were installed only after 88 participants were already enrolled. N‑MOmentum study used a complex 18 clinical criteria including imaging to minimize the risk of missing an event. The SAkura study criteria for relapse adjudication were solely clinically based (EDSS/FSS change) and may be more applicable in clinical practice.

In clinical practice, IV infusions of eculizumab are required every 2 weeks and must be rigorously followed as complement component 5 activity begins to rise within a few days of a missed dose. Inebilizumab requires two infusions at start and then only two infusions per year. The SC formulation of satralizumab allows self‑administration at home.

Due to these differences between the four trials, comparisons across trials cannot be made, and should be interpreted based

| Trial                  | Prevent | N-MOmentum | SAkuraSky | SAkuraStar |
|------------------------|---------|------------|-----------|------------|
| Drug                   | Eculizumab | Inebilizumab | Satralizumab | Satralizumab |
| Target                 | C5      | CD19       | IL6 receptor | IL6 receptor |
| Route and dose         | IV, 900 mg q1 week×4 doses then 1200 mg q2 weeks | IV, 300 mg 2 weeks apart then q6 months | SC, 120 mg on weeks 0, 2, 4 then q4 weeks | SC, 120 mg on weeks 0, 2, 4 then q4 weeks |
| Randomization          | 2:1     | 3:1        | 1:1       | 2:1        |
| Concomitant immunosuppression | Yes     | No         | Yes       | No         |
| Preceding disease activity inclusion criteria | ≥ 2 relapses in 12 months or ≥3 relapses in 24 months with 1 in 12 months | ≥ 1 relapse in 12 months or ≥2 relapses in 24 months | ≥2 relapses in 24 months with 1 in 12 months | ≥1 relapse in 12 months |
| Age inclusion criteria (years) | ≥ 18 | ≥ 18 | 12-74 | 18–74 |
| EDSS inclusion criteria | ≤ 7 | ≤ 8 | ≤ 6.5 | ≤ 6.5 |
| Number of patients (verum: placebo) | 143 (96:47) | 230 (174:56) | 83 (41:42) | 95 (63:32) |
| Age (verum vs. placebo) | 43.9 versus 45.0 | 43.0 versus 42.6 | 40.8 versus 43.0 | 45.3 versus 40.5 |
| Female sex (%) | 92 versus 89 | 91 versus 89 | 90 versus 95 | 73 versus 97 |
| AQP4-IgG:±IgG (%) | 143 (100) | 213:17 (93) | 55:28 (66) | 64:31 (67) |
| EDSS at basal | 4.0 versus 4.0 (median) | 3.5 versus 4.0 (median) | 3.8 versus 3.6 (mean) | 3.9 versus 3.7 (mean) |
| Primary endpoint | Time to first relapse | Time to first adjudicated relapse | Time to first protocol defined relapse | Time to first protocol defined relapse |
| Relapse rate (%) (HR, 95 CI) | 3 versus 43 (0.06, 0.02-0.20) | 12 versus 39 (0.272, 0.15-0.496) | 20 versus 43 (0.38, 0.16-0.88) | 30 versus 50 (0.45, 0.23-0.89) |
| Relapse rate reduction (%) | 94 | 73 | 62 | 55 |
| Relapse rate reduction in AQP4-IgG (%) | 94 | 77 | 79 | 74 |
| Relapse free at 48 weeks (%) | 89 versus 51 | - | 89 versus 66 | 76 versus 62 |
| Relapse free at 96 weeks (%) | 85 versus 36 | - | 78 versus 59 | 72 versus 51 |
| Relevant secondary outcomes | Improved adjudicated ARR; but no impact on EDSS and QoL | Reduced participants with EDSS worsening | No change in fatigue or pain | No change in fatigue or pain |
| Common adverse events (death) | Upper respiratory infection, headache (1 death pulmonary empyema) | Urinary tract infection, arthralgia (2 deaths in open label extension; 1 respiratory insufficiency related to NMOSD, 1 indeterminate) | Nasopharyngitis, upper respiratory infection, headache (no deaths or anaphylactic reactions) | Upper respiratory infection, urinary tract infection (no deaths or anaphylactic reactions) |
| Infections Reference | Pittock et al., 2019[80] | Not reported | Cree et al., 2019[81] | Similar to placebo |
| Reference | Yamamura et al., 2019[85] | Traboulsee et al., 2020[84] | similar to placebo |
| Trial registration | NCT01892345 | NCT02200770 | NCT02028884 | NCT02073279 |

EDSS=Expanded disability status scale, AQP4=Aquaporin-4, IgG=immunoglobulin G, AQP4-IgG±=AQP4-IgG seropositive, AQP4-IgG−=AQP4-IgG seronegative, HR=Hazard ratio, CI=Confidence interval, IL6=Interleukin 6, IV=Intravenous, SC=Subcutaneous, ARR=Annualized relapse rate, QoL=Quality of life, NMOSD=Neuromyelitis optica spectrum disorder
on the study designs. All the approved drugs are effective and safe for treating NMOSD. The choice of treatment depends on the decision of the health care professional and the patient, taking into account medical and patient assessments such as efficacy and safety of the treatment, previous medication and current disease state, comorbidities, preferred route of administration, and lifestyle.

**Emerging Therapies**

Despite the three new biologicals eculizumab, inebilizumab, and satralizumab as well as the off-label maintenance therapies like azathioprine, mycophenolate mofetil, or rituximab were established, therapy-refractory patients still pose a challenge. Restoring immune tolerance might provide an interesting treatment strategy in the future. Some success was achieved by using autologous hematopoietic stem cell transplantation, peptide-loaded tolerogenic dendritic cells, DNA vaccine encoding myelin basic protein, autoactive T cell vaccination and regulatory T cells. Further alternative targets for NMOSD treatments are blood-brain barrier, complement cascade, granulocytes, and B cells. Another approach is engineered, monoclonal anti-AQP4 antibodies that block the binding of AQP4-IgG autoantibodies and lack cytotoxicity effector functions.

**Conclusion**

Quick diagnosis and prompt treatment are crucial for saving visual or neurology function in acute stage. Effective maintenance treatment is the other key to prevent patient from disability. We have to keep in mind that patients with NMOSD-ON may develop concurrent transverse myelitis or other CNS disease. Therefore, the patient may be referred to a diversified care team, including neurologists, physiatrists and psychiatrists, to implement further management.

**Acknowledgments**

We thanked Chugai Pharma Taiwan Co, Ltd. for comments and funding medical editing that greatly improved the manuscript.

**Financial support and sponsorship**

This medical editing was funded by Chugai Pharma Taiwan Co, Ltd.

**Conflicts of interest**

The authors declare that there are no conflicts of interests of this paper.

**References**

1. Stunkel L, Kung NH, Wilson B, McClelland CM, Van Stavern GP. Incidence and causes of overdiagnosis of optic neuritis. JAMA Ophthalmol 2018;136:76-81.
2. Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 2020;11:501.
3. Papp V, Illes Z, Magyari M, Koch-Henriksen N, Kant M, Pfleger CC, et al. Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 2018;91:e2265-75.
4. Bukhari W, Prain KM, Waters P, Woodhall M, O’Gorman CM, Clarke L, et al. Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 2017;88:632-8.
5. Fang CW, Wang HP, Chen HM, Lin JW, Lin WS. Epidemiology and comorbidities of adult multiple sclerosis and neuromyelitis optica in Taiwan, 2001-2015. Mult Scler Relat Disord 2020;45:102425.
6. Kitley J, Leite MI, Nakashima I, Waters P, McNeilis B, Brown R, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012;135:1834-49.
7. Quek AM, McKeon A, Lennon VA, Mandrekar JN, Iorio R, Jiao Y, et al. Effects of age and sex on aquaporin-4-autoimmunity. Arch Neurol 2012;69:1039-43.
8. Bove R, Elsone L, Alvarez E, Borisov N, Cortez MM, Mateen FJ, et al. Female hormonal exposures and neuromyelitis optica symptoms onset in a multicenter study. Neurol Neuroimmunol Neuroinflamm 2017;4:e339.
9. Pittock SJ, Lucchinetti CF. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: A decade later. Ann N Y Acad Sci 2016;1366:20-39.
10. Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero-Romero S, et al. Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler 2018;24:1843-51.
11. Li X, Zhang C, Jia D, Fan M, Li T, Tian DC, et al. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis. Mult Scler Relat Disord 2021;53:103030.
12. Kessler RA, Mealy MA, Levy M. Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;3:e269.
13. Schmidt F, Zimmermann H, Mikolajczak J, Oertel FC, Pache F, Weinhold M, et al. Severe structural and functional visual system damage leads to profound loss of vision-related quality of life in patients with neuromyelitis optica spectrum disorders. Mult Scler Relat Disord 2017;11:45-50.
14. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:1107-14.
15. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinschenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805-15.
16. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
17. Prain K, Woodhall M, Vincent A, Barnett MH, Bundell CS, et al. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol 2019;10:1028.
18. Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 2019;15:89-102.
19. Sharma J, Bhatti MT, Danesh-Meyer HV. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review. Clin Exp Ophthalmol 2021;49:186-202.
20. Collongues N, Ayme-Dietrich E, Monassier L, de Seze J, Taiwan J Ophthalmol - Volume 12, Issue 3, July-September 2022
Optical
Intravenous
Low-dose corticosteroids reduce relapses
Retinal optical coherence tomography in
Apheresis therapies for NMOSD attacks:
Taiwan J Ophthalmol
36. Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Sawai S,
35. Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I,
34. Duan T, Smith AJ, Verkman AS. Complement-independent
33. Bennett JL, de Seze J, Zamvil SS, Hemmer B,
32. Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H,
31. Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J,
30. Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT,
29. Huang Y, Zhou L, Zhang Bao J, Cai T, Wang B, Li X,
28. Oertel FC, Specovius S, Zimmermann HG, Chien C, Motamedi S,
27. Nakajima H, Hosokawa T, Sugino M, Kimura F, Sugawara J,
26. Rogaczewska M, Michalak S, Stopa M. Differentiation between
25. Liu C, Xiao H, Zhang X, Zhao Y, Li R, Zhong X,
23. Bennett JL, de Seze J, Lana‑Peixoto M, Palace J, Waldman A,
22. De Lott LB, Bennett JL, Costello F. The changing landscape of
Nemoto J, Clin Chim Acta Int J Clin Chem 2017;469:144‑9.
neurological disorders: A special focus on neuromyelitis optica.
Neuroinflamm 2020;7:e841.
Neuropathol Commun 2019;7:112.
produced by antibody‑dependent cellular cytotoxicity. Acta
bystander injury in AQP4‑IgG seropositive neuromyelitis optica
with multiple B‑cell compartments in neuromyelitis optica
aquaporin‑4 antibodies from circulating B cells in neuromyelitis
antibody‑positive neuromyelitis optica spectrum disorders and in multiple
sclerosis. Mult Scler J Exp Transl Clin 2018;4:2055217318791196.
doi: 10.1177/2055217318791196.
Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neuro 2010;10:45.
Retinal optical coherence tomography in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2021;8:e1068.
Huang Y, Zhou L, Zhang Bao J, Cai T, Wang B, Li X, et al. Peripapillary and parafoveal vascular network assessment by
optical coherence tomography angiography in aquaporin‑4 antibody‑positive neuromyelitis optica spectrum disorders. Br J Ophthalmol 2019;103:789‑96.
Khanne S, Sharma A, Huecker J, Gordon M, Nasmith RT, Van Staven GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012;32:216‑20.
Wilson R, Makuch M, Kienzler AK, Varley J, Taylor J, Woodhall M, et al. Condition‑dependent generation of aquaporin‑4 antibodies from circulating B cells in neuromyelitis optica. Brain 2010;141:1063‑74.
Kowarik MC, Astling D, Gasperi C, Wemlinger S, Schumann H, Dziewiatkowska M, et al. CNS Aquaporin‑4‑specific B cells connect with multiple Bcell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol 2017;4:369‑80.
Bennett JL, O optica spectrum diso Zamvil SS, Hemmer B, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e104.
Duan T, Smith AJ, Verkman AS. Complement-independent bystander injury in AQP4‑IgG seropositive neuromyelitis optica produced by antibody‑dependent cellular cytotoxicity. Acta Neuropathol Commun 2019;7:112.
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinschenker BG, et al. Interleukin‑6 in neuromyelitis optica spectrum disorder pathophysiology. Neurol Neuroimmunol Neuroinflamm 2020;7:e841.
Uzawa A, Mori M, Masuda H, Ohtani R, Uchida T, Sawai S, et al. Interleukin‑6 analysis of 572 consecutive CSF samples from neurological disorders: A special focus on neuromyelitis optica. Clin Chim Acta Int J Clin Chem 2017;469:144‑9.
Takeshita Y, Fujikawa S, Serizawa K, Fujisawa M, Matsuo K, Nemoto J, et al. New BBB model reveals that IL‑6 blockade suppressed the BBB disorder, preventing onset of NMOSD. Neurol Neuroimmunol Neuroinflamm 2021;8:e1076.
Marignier R, Hacohen Y, Cobo‑Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, et al. Myelin‑oligodendrocyte glycoprotein antibody‑associated disease. Lancet Neurol 2021;20:762‑72.
Takai Y, Misu T, Kaneko K, Chihara N, Narikawa K, Tsuchida S, et al. Myelin oligodendrocyte glycoprotein antibody‑associated disease: An immunopathological study. Brain 2020;143:1431‑46.
Kleiter I, Gahlen A, Borisov N, Fischer K, Wenneke KD, Wegner B, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016;79:206‑16.
Sherman E, Han MH. Acute and chronic management of neuromyelitis optica spectrum disorder. Curr Treat Options Neurol 2015;17:48.
Kleiter I, Gahlen A, Borisov N, Fischer K, Wenneke KD, Hellwig K, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018;5:e504.
Bonnan M, Valentinio R, Debeugny S, Merle H, Fergé JL, Mehdouai H, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:346‑51.
Stiebel-Kalish H, Hellmann MA, Mimouni M, Faul F, Bialer O, Bach M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 2019;6:e572.
Nakamura M, Nakazawa T, Doi H, Hariya T, Omokada K, Misu T, et al. Early high‑dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol 2010;248:1777‑85.
Abboud H, Petrak A, Mealy M, Sadidharan S, Siddique L, Levy M. Treatment of acute relapses in neuromyelitis optica: Steroids alone versus steroids plus plasma exchange. Mult Scler 2016;22:185‑92.
Seifert CL, Wegner C, Sprenger T, Weber MS, Brück W, Hemmer B, et al. Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B‑cell response. Mult Scler 2012;18:1045‑9.
Sriritho S, Nop sopon T, Pongpirul K. Therapeutic plasma exchange vs. conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): A systematic review and meta‑analysis. J Neurol 2021;268:4549‑62.
Deschamps R, Gueguen A, Parquet N, Sabe S, Driss F, Mesnil M, et al. Plasma exchange response in 34 patients with severe optic neuritis. J Neurol 2016;263:883‑7.
Merle H, Olindo S, Jeannin S, Valentino R, Mehdouai H, Cabot F, et al. Treatment of optic neuritis by plasma exchange (add‑on) in neuromyelitis optica. Arch Ophthalmol 2012;130:858‑62.
Traub J, Häusser-Kinzsel S, Weber MS. Differential effects of MS therapeutics on B cells‑implications for their use and failure in AQP4‑positive NMOSD patients. Int J Mol Sci 2020;21:5021.
Elson E, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: Experience in 10 patients. Mult Scler 2014;20:501‑4.
Li X, Tian DC, Fan M, Xiu Y, Wang X, Li T, et al. Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders (NMOSD). Mult Scler Relat Disord 2020;44:102325.
Mader S, Kumpel T, Mein E. Novel insights into pathophysiology and therapeutic possibilities reveal further differences between AQP4‑IgG and MOG‑IgG‑associated diseases. Curr Opin Neurol 2020;33:362‑71.
Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low‑dose corticosteroids reduce relapses in neuromyelitis optica: A retrospective analysis. Mult Scler 2007;13:968‑74.
Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 2021;49:102750.

Liu YH, Guo YC, Lin LY, Tsai CP, Fuh JL, Wang YF, et al. Treatment response, risk of relapse and clinical characteristics of Taiwanese patients with neuromyelitis optica spectrum disorder. J Formos Med Assoc 2021;59:299-646 (21) 00499-X. [doi: 10.1016/j. jfma. 2021.11.002].

Chan KH, Lee CY. Treatment of neuromyelitis Optica Spectrum Disorders. Int J Mol Sci 2022;22:8638.

Kim SH, Kim W, Li XF, Jung JJ, Kim HJ. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult Scler 2012;18:1480-3.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012;69:239-45.

Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler 2012;18:113-5.

Levy M, Fujihara K, Palace J. New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 2020;19:391-401.

Luo D, Wei R, Tian X, Chen C, Ma L, Li M, et al. Efficacy and safety of azathioprine for neuromyelitis optica spectrum disorders: A meta-analysis of real-world studies. Mult Scler Relat Disord 2020;46:102484.

Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, Paul F, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler 2018;24:1737-42.

Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-7.

Nikoo Z, Badhian S, Shaygannejad V, Asgari N, Ashhari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: A randomized clinical trial. J Neurol 2017;264:2003-9.

Elson L, Kitley J, Luppe S, Lythgoe D, Mutch K, Jacob S, et al. Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: A multicentre retrospective observational study from the UK. Mult Scler 2014;20:1533-40.

Songwisit S, Kosiyakul P, Jitprapaikulsan J, Prayoonwiwat N, Ungprasert P, Siritho S. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis. Sci Rep 2020;10:16727.

Wang Y, Ma J, Chang H, Zhang X, Yin L. Efficacy of mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta-analysis. Mult Scler Relat Disord 2021;55:103181.

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment efficacy. JAMA Neurology 2017;74:2113-20.

Montcuquet A, Collongues N, Papeix C, Zephir H, Audoin B, Laplaud D, et al. Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG-MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 2017;23:1377-84.

Tahara M, Oeda T, Okada K, Kiriyama T, Ochi K, Maruyama H, et al. Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2020;19:298-306.

Tahara M, Oeda T, Okada K, Ochi K, Maruyama H, Fukaura H, et al. Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN2 study): B cell monitoring-based administration. Mult Scler Relat Disord 2022;60:103730.

Loton I, McGowan R, Levy M. Anti-IL-6 therapies for neuromyelitis optica spectrum disorders: A systematic review of safety and efficacy. Curr Neuropsychopharmacol 2021;19:220-32.

Zhang C, Zhang M, Qiu W, Ma H, Zhang X, Zhu Z, et al. Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): An open-label, multicentre, randomised, phase 2 trial. Lancet Neurol 2020;19:391-401.

Rinkelstein M, Ayzenberg I, Lindenblatt G, Fischer K, Gahlen A, Novi G, et al. Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2022:e1100.

Thomas TC, Rollins SA, Rother RP, Giannoni MA, Hartman SL, Elliott EA, et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv. Mol Immunol 1996;33:1389-401.

Tradtrantip L, Felix CM, Spirig R, Morelli AB, Verkman AS. Recombinant IgG1 Fc hexamers block cytotoxicity and pathologocal changes in experimental in vivo and rat models of neuromyelitis optica. Neuropharmacology 2018;133:345-53.

Pittok SJ, Lennon VA, McKeon A, Mandrekar J, Weinsenker BG, Lucchetti CF, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: An open-label pilot study. Lancet Neurol 2013;12:554-62.

Pittok SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:614-25.

Cree BA, Bennett JL, Kim HJ, Weinsenker BG, Pittok SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): A double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019;394:1352-63.

Heo YA. Satralizumab: First Approval. Drugs 2020;80:1477-82.

Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, Shimaoka S, et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol 2010;28:1203-7.

Traboulsee A, Greenberg BM, Bennett JL, Szczeschowski L, Fox E, Shkrobat S, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: A randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol 2020;19:402-12.

Yamamura T, Kleitman I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 2019;381:2114-24.

Wijnsma KL, Ter Heine R, Moejs DJ, Langemeijer S, Schols SE, Volokhina EB, et al. Pharmacology, pharmacokinetics and pharmacodynamics of eculizumab, and possibilities for an individualized approach to eculizumab. Clin Pharmacokinet 2019;58:859-74.

Zhang P, Liu B. Effect of autologous hematopoietic stem cell transplantation on multiple sclerosis and neuromyelitis optica spectrum disorder: A PRISMA-compliant meta-analysis. Bone Marrow Transplant 2020;55:1928-34.

Zubizaretta I, Flórez-Grau G, Vila G, Cabezón R, España C, Andorra M, et al. Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase Ib trial. Proc Natl Acad Sci U S A 2019;116:8463-70.

Garren H, Robinson WH, Krasulová E, Havrdová E, Nadj C, Selmaj K, et al. Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis. Ann Neurol 2008;63:611-20.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, et al. Effects of mycophenolate mofetil on multiple sclerosis and neuromyelitis optica spectrum disorders: An open-label pilot study. Mult Scler 2012;18:1480-3.
Clare-Salzler M, et al. Restoring immune tolerance in neuromyelitis optica: Part II. Neurol Neuroimmunol Neuroinflamm 2016;3:e277.
91. Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin FS, Clare-Salzler M, et al. Restoring immune tolerance in neuromyelitis optica: Part I. Neurol Neuroimmunol Neuroinflamm 2016;3:e276.
92. Shimizu F, Nishihara H, Kanda T. Blood-brain barrier dysfunction in immuno-mediated neurological diseases. Immunol Med 2018;41:120-8.
93. Asavapanumas N, Tradtrantip L, Verkman AS. Targeting the complement system in neuromyelitis optica spectrum disorder. Expert Opin Biol Ther 2021;21:1073-86.
94. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: State-of-the-art and emerging therapies. Nat Rev Neurol 2014;10:493-506.
95. Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al. Targeting B cells to modify MS, NMO, and MOGAD: Part 2. Neurol Neuroimmunol Neuroinflamm 2021;8:e919.
96. Graf J, Mares J, Barnett M, Aktas O, Albrecht P, Zamvil SS, et al. Targeting B cells to modify MS, NMO, and MOGAD: Part 1. Neurol Neuroimmunol Neuroinflamm 2021;8:e918.
97. Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS. Affinity-matured ‘aquaporumab’ anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology 2020;162:107827.
98. Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314-22.